Research Paper Volume 11, Issue 7 pp 2151—2176

Pyridoxine 5′-phosphate oxidase is correlated with human breast invasive ductal carcinoma development

Figure 3. Analysis of the correlation between the expression level of PNPO and the overall survival (OS) of patients with IDC. PNPO expression was classified into two groups: PNPO low and PNPO high. The OS rate of 127 IDC patients was estimated by Kaplan-Meier analysis. The survival plots of IDC patients are shown. (A) Patients with low and high expression of PNPO. a vs. b: P=0.2575. (B) Patients with low and high expression of PNPO in age low (≤60 years) and high (>60 years) groups. a vs. b: P=0.6034; c vs. d: P=0.5127; a vs. c: P=0.5514; b vs. d: P=0.9694; a vs. d: P=0.5215; b vs. c: P=0.5442. (C) Patients with low and high expression of PNPO in non-metastasis and metastasis groups. a vs s. b: P=1.0000; c vs. d: P=0.3299; a vs. c: P=0.2024; b vs. d: P=0.0128; a vs. d: P=0.0385; b vs. c: P=0.1782. (D) Patients with low and high expression of PNPO in small (≤2 cm) and large (>2 cm) tumor groups. a vs. b: P=1.0000; vs. d: P=0.3339; a vs. c: P=0.3527; b vs. d: P=0.0459; a vs. d: P=0.1953; b vs. c: P=0.3173. (E) Patients with low and high expression of PNPO in low grade (1+2) and high grade (3) groups. a vs. b: P=0.1169; c vs. d: P=0.4070; a vs. c: P=0.2024; b vs. d: P=0.2542; a vs. d: P=1.0000; b vs. c: P=0.6708. (F) Patients with low and high expression of PNPO in early (I+II) and later (III+IV) stage groups. a vs. b: P=1.0000; c vs. d: P=0.5600; a vs. c: P=0.0253; b vs. d: P=0.0009; a vs. d: P=0.0112; b vs. c: P=0.0223. (G) Patients with low and high expression of PNPO in ER low and high expression groups. a vs. b: P=0.4315; c vs. d: P=0.4520; a vs. c: P=0.4328; b vs. d: P=0.4912; a vs. d: P=0.7461; b vs. c: P=0.3919. (H) Patients with low and high expression of PNPO in PR low and high expression groups. a vs. b: P=0.6074; c vs. d: P=0.6547; a vs. c: P=0.5514; b vs. d: P=0.4993; a vs. d: P=0.3594; b vs. c: P=1.0000. (I) Patients with low and high expression of PNPO in HER2 low and high expression groups. a vs. b: P=0.4549; c vs. d: P=0.9261; a vs. c: P=0.3404; b vs. d: P=0.8380; a vs. d: P=0.3404; b vs. c: P=0.9143. (J) Patients with low and high expression of PNPO in less (≤10) and more (>10) Ki-67 positive groups. a vs. b: P=0.9372; c vs. d: P=0.6048; a vs. c: P=0.4096; b vs. d: P=0.7686; a vs. d: P=0.9474; b vs. c: P=0.3711.